The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | Functional differences between trispecific antibodies and bispecific antibodies in lymphoma
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the functional differences between trispecific antibodies and bispecific antibodies in targeting lymphoma. Dr Westin highlights that trispecific antibodies have the potential to bind to two different antigens on the cancer cell, reducing the likelihood of immune escape due to loss of an antigen. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Trispecific antibodies are a novel way to target malignancies, and they have some significant differences from bispecific antibodies. Obviously, the first is the third antigen being targeted, hence the word tri, versus bispecific antibodies often have one antigen on the tumor, one antigen on the immune cell, bispecific. Trispecifics have the advantage of potentially having two ways to target the cancer cell so that if one antigen is lost, the other antigen on the cancer cell hopefully will still be there...
Trispecific antibodies are a novel way to target malignancies, and they have some significant differences from bispecific antibodies. Obviously, the first is the third antigen being targeted, hence the word tri, versus bispecific antibodies often have one antigen on the tumor, one antigen on the immune cell, bispecific. Trispecifics have the advantage of potentially having two ways to target the cancer cell so that if one antigen is lost, the other antigen on the cancer cell hopefully will still be there. And so there should be a lower chance of immune escape by loss of an antigen, just because there are two chances for the antibody to bind to the cancer cell and to then bind to the T-cell. So trispecific antibodies have significant theoretical advantages, although as of yet, we haven’t seen late-stage clinical trials with trispecific antibodies to validate that is practically a reality or if that’s a theoretical advantage.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
